Occult Primary
Cervical nodal metastases of unknown primary origin
DefinitionClick to collapse
Occult primary tumors, also termed cancers of unknown primary (CUP), are defined as histologically confirmed metastatic malignancies for which a primary anatomical site cannot be identified after a standard pretreatment evaluation [1,2]. These tumors are characterized by early dissemination, aggressive clinical behavior, and unpredictable patterns of metastasis [3]. The median overall survival (OS) for patients with CUP is 8 to 12 months, although select patients with favorable prognostic subsets may achieve median OS in the range of 12 to 36 months [2,4,5]. The majority of CUP cases are epithelial in origin, with the most frequent histologic subtypes being adenocarcinoma (well- or moderately differentiated, 60%; poorly differentiated, 25%), squamous cell carcinoma (SCC, 5%), undifferentiated carcinoma (5%), and neuroendocrine tumors (5%) [1,2,27]. The NCCN Guidelines for Occult Primary focus on two major pathologic diagnoses: adenocarcinoma or carcinoma not otherwise specified, and squamous cell carcinoma; neuroendocrine tumors and head and neck occult primaries are managed according to their respective disease-specific guidelines [OCC-1, OCC-2, Discussion MS-2].
EpidemiologyClick to collapse
CUP has an average age at diagnosis of 60 to 75 years and accounts for 2% to 9% of all malignant tumors [2,8]. It is among the 10 most frequently diagnosed cancers in developed countries [2,9]. In the United States, an estimated 67,800 cases of cancer from other and unspecified primary sites are expected to be diagnosed in 2026, representing approximately 3.2% of all US cancers [10,11]. Deaths from these tumors are projected to reach 54,310 in 2026 [10]. The incidence of CUP diagnoses has been decreasing, likely due to improved diagnostic techniques that detect primary tumors, but no improvement in survival has been reported [12,13]. A study using the Swedish Family-Cancer Database revealed that 2.8% of occult primary cases are familial (parent and offspring both diagnosed), and CUP is associated with the occurrence of lung, kidney, and colorectal cancers in families, suggesting these are often the primary sites [14]. A latent primary cancer may emerge during the disease course in 20%β50% of cases, but postmortem examination fails to identify the primary in 20%β50% of patients [8,15,16]. An epidemiologic correlation between smoking and CUP risk has been observed: individuals who smoked >20 cigarettes per day had a strong association (multivariable adjusted hazard ratio [HR] 1.45; 95% CI 1.09β1.94; P trend = .02) for those who smoked β₯40 years compared to never smokers [17]. CUP occurs across racial and ethnic groups, but specific race-stratified incidence data were not provided in the source. The median OS for the majority of patients (about 80%) is 3 to 10 months, with adenocarcinomas and undifferentiated tumors having worse prognosis than SCC (3.5% vs 41.6% 3-year survival) [2,21].
SubtypesClick to collapse
Adenocarcinoma (well- or moderately differentiated)
The most common subtype, accounting for approximately 60% of CUP cases. Tumors exhibit glandular differentiation on light microscopy.
Adenocarcinoma (poorly differentiated)
Represents approximately 25% of CUP cases. Tumors show limited glandular differentiation and higher nuclear grade.
Squamous cell carcinoma (SCC)
Accounts for about 5% of CUP cases. Characterized by squamous differentiation on histology and cytokeratin 5/6, p63/p40 positivity.
Undifferentiated carcinoma
Comprises approximately 5% of CUP cases. Tumors lack recognizable differentiation on light microscopy.
Neuroendocrine tumors
Account for approximately 5% of CUP cases. Include well-differentiated neuroendocrine tumors (carcinoids) and poorly differentiated neuroendocrine carcinomas (PDNEC).
Molecular PathogenesisClick to collapse
CUP tumors harbor multiple chromosomal abnormalities and overexpression of various oncogenes and tumor suppressor genes. Common genomic alterations include deletions in tumor suppressor genes p53 (49.6%), CDKN2A (19.0%), and NOTCH1 (14.1%), as well as activation of oncogenes KRAS (23.4%), FGFR4 (14.9%), and PIK3CA (10.7%) [33]. Other frequently altered genes include EGFR, MET, JAK3, BRAF, c-kit/PDGFR (PDGFRΞ± or PDGFRΞ²), RAS, BCL2, HER2, and TP53 [9,28-30]. Activation of angiogenesis genes is observed in 50%β89% of CUP tumors, oncogene overexpression in 10%β30%, epithelial-to-mesenchymal transition marker elevation in 16%, activation of hypoxia-related proteins in 25%, and intracellular signaling molecule activation in 20%β35% [2]. The BRD4-NUT oncogene, resulting from the chromosomal translocation t(15;19), has been identified in children and young adults with carcinoma of midline structures and unclear primary sites [1,31,32]. Chromosomal instability has been suggested as a possible cause or prognostic factor for more aggressive presentations of CUP [2,34]. Both KRAS activation and CDKN2A deletion are associated with poor prognosis [33]. Comprehensive genomic profiling using next-generation sequencing can identify potentially actionable alterations in 30%β85% of patients, including mutations in BRAF V600E, NTRK1/2/3 fusions, RET fusions, HER2 amplification, and markers of microsatellite instability (MSI) and high tumor mutational burden (TMB-H) [24,74,78-82]. The tumor mutational landscape in CUP may guide site-specific therapy and biomarker-driven treatment strategies [OCC-B, Discussion MS-7].
Risk FactorsClick to collapse
Cigarette smoking
Strong association between smoking and risk of developing CUP. Frequency (>20 cigarettes per day) and duration (β₯40 years) increase risk. Multivariable adjusted HR 1.45 (95% CI 1.09β1.94; P trend = .02) for those who smoked β₯40 years compared to never smokers.
Familial/genetic predisposition
2.8% of CUP cases are familial (parent and offspring both affected). CUP is associated with familial occurrence of lung, kidney, and colorectal cancers, suggesting these may be the primary sites.
Age (β₯65 years)
Older age is an unfavorable prognostic factor, but also a risk factor for developing CUP given median age at diagnosis of 60-75 years. However, the source does not explicitly state age as a causative risk factor; it is more a demographic characteristic.
Male gender
Male gender assigned at birth is associated with worse prognosis and may influence incidence, but source does not provide specific incidence by gender. In prognostic models, male gender is associated with worse survival.
Clinical FeaturesClick to collapse
Typical Presentation
Cancer of unknown primary (CUP) typically presents in patients aged 60β75 years with metastases from an unidentified primary site. The most common sites of involvement are the liver, lungs, bones, and lymph nodes, and more than 50% of patients present with multiple metastatic sites [2], [18]. Approximately 80% of patients have an unfavorable prognosis with median overall survival (OS) of 3β10 months; however, a favorable subset (approximately 20%) may achieve median OS of 12β36 months [2], [4], [5]. Classic presentations include cervical lymphadenopathy from squamous cell carcinoma (SCC), axillary adenopathy in women suggesting occult breast cancer, midline nodal distribution in young men suggesting germ cell tumors, and peritoneal carcinomatosis in women suggesting ovarian primary. Symptoms are often nonspecific and include fatigue, weight loss, pain at metastatic sites, and organ-specific complaints such as dyspnea (pleural effusion), abdominal distension (ascites), or bone pain. The diagnosis is made after standard pretreatment evaluation fails to identify a primary tumor [1], [2].
Symptoms
Weight loss
Unintentional weight loss is common, often reflecting advanced disease and catabolic state.
Fatigue
Generalized weakness and fatigue are among the most common nonspecific symptoms.
Pain
Pain localized to the site of metastasis (e.g., bone pain, abdominal pain, chest pain).
Dyspnea
Shortness of breath related to pleural effusion, lung nodules, or lymphangitic spread.
Abdominal distension
Abdominal swelling due to ascites or peritoneal carcinomatosis.
Neurologic deficits
Headache, seizures, focal deficits from brain metastases.
Signs
Palpable lymphadenopathy
Cervical, supraclavicular, axillary, or inguinal lymph node enlargement. May be firm, fixed, or matted.
Hepatomegaly
Enlarged liver due to metastatic deposits.
Ascites
Abdominal fluid wave, shifting dullness, often with peritoneal carcinomatosis.
Pleural effusion
Decreased breath sounds, dullness to percussion on chest exam.
Bone tenderness
Pain on palpation over metastatic bone lesions.
Skin lesions
Cutaneous metastases may rarely be the presenting sign; primary skin cancer must be excluded.
Red FlagsClick to collapse
Poor performance status (ECOG β₯2) is a strong independent predictor of worse survival [5].
Multiple organ involvement (liver, lung, bone) at presentation [2].
Nonpapillary malignant ascites from adenocarcinoma [2].
Multiple cerebral metastases [2].
Bone lesions in weight-bearing areas with potential for pathologic fracture [OCC-10].
Impending spinal cord compression [OCC-C].
Rapid disease progression or symptomatic decline despite initial therapy.
Male gender assigned at birth and older age (β₯65 years) are unfavorable prognostic factors [2].
High neutrophil-lymphocyte ratio (NLR) [5].
Psychosocial distress: significant anxiety/depression due to uncertainty of diagnosis, which may impair treatment acceptance [OCC-1 footnote a].
Unexplained weight loss >10% over 3 months.
Elevated LDH may indicate high tumor burden.
InvestigationsClick to collapse
Diagnostic
Complete history and physical (H&P) including breast, GU, pelvic, rectal, skin, and oral cavity exam
Identify potential primary sites; review past biopsies, removed lesions, spontaneously regressing lesions, and existing imaging.
Core needle biopsy (preferred) or FNA with cell block of most accessible metastatic lesion
Obtain adequate tissue for histologic diagnosis and ancillary studies.
Complete blood count (CBC) and comprehensive metabolic panel (CMP)
Baseline assessment; detect anemia, liver or renal dysfunction, electrolyte abnormalities.
Lactate dehydrogenase (LDH) as indicated
Prognostic marker; elevated LDH associated with higher tumor burden.
Chest/abdomen/pelvis CT with contrast (or MRI with contrast if contraindicated; FDG-PET/CT alternative)
Comprehensive imaging to identify primary tumor and extent of metastases.
Clinically directed endoscopy
To visualize potential primary sites in GI, GU, or respiratory tract if symptoms or IHC suggest.
Immunohistochemistry (IHC) panel (see OCC-A)
Determine cell lineage (carcinoma, lymphoma, melanoma, germ cell, mesothelioma) and identify putative primary site.
In situ hybridization (ISH) for HPV (p16), EBV
HPV/p16 positivity suggests oropharyngeal SCC; EBV positivity suggests nasopharyngeal primary [OCC-11 footnote q].
MSI/MMR testing (IHC for MMR or PCR for MSI)
Identify dMMR/MSI-H tumors that may respond to immune checkpoint inhibitors. Low prevalence in CUP (<2%) [84].
HER2 IHC
Identify HER2-positive (IHC 3+) tumors eligible for fam-trastuzumab deruxtecan-nxki.
Biomarker testing using NGS (tumor tissue or cell-free DNA) for gene alterations and TMB
Identify actionable mutations (BRAF V600E, NTRK fusions, RET fusions, MSI-H, TMB-H) for targeted therapy or immunotherapy.
Staging
Chest/abdomen/pelvis CT with contrast (or MRI) β as above
Standard imaging to assess extent of disease and guide management.
FDG-PET/CT
Alternative if contrast contraindicated; may detect occult primary and additional metastases (sensitivity ~97% for cervical nodes) [91].
Brain MRI with contrast
Evaluate for brain metastases in patients with neurologic symptoms or multiple sites of involvement.
Bone scan (or FDG-PET/CT plus CT bone windows)
Detect bone metastases, especially if painful or potential pathologic fracture.
Mammogram (plus breast MRI and/or ultrasound if nondiagnostic and histopathologic evidence for breast cancer)
Identify occult breast primary in patients with axillary, supraclavicular, mediastinal, or other metastatic patterns suggestive of breast cancer.
Serum tumor markers (PSA, CA-125, AFP, hCG, CA 19-9, CA 15-3 as clinically indicated)
Elevations can suggest primary site (PSA for prostate, CA-125 for ovary, AFP/hCG for germ cell). Not diagnostic but may guide workup.
Testicular ultrasound (if AFP/hCG elevated or clinical suspicion)
Identify testicular germ cell primary.
Urine cytology Β± cystoscopy
Evaluate for urothelial primary.
Proctoscopy / anoscopy
Evaluate for anal or rectal primary.
Gynecologic oncology consult
To evaluate ovarian/primary peritoneal cancer, especially in females with peritoneal/ascites or elevated CA-125.
Biomarkers
NGS panel for gene alterations (including BRAF, NTRK, RET, MSI, TMB)
Identify targetable alterations for biomarker-driven therapy (dabrafenib/trametinib, entrectinib/larotrectinib/repotrectinib, selpercatinib, pembrolizumab).
PD-L1 testing
May identify patients likely to respond to immune checkpoint inhibitors, though not mandatory for pembrolizumab in dMMR/MSI-H or TMB-H.
TRK protein IHC (per physician discretion)
Screening for NTRK fusions; positive results should be confirmed with NGS [OCC-A footnote 2].
DPYD testing
Identify DPYD deficiency to prevent severe fluorouracil toxicity.
StagingClick to collapse
No formal AJCC TNM staging system exists for Occult Primary (CUP). Instead, patients are stratified by prognostic groups (favorable vs unfavorable) based on clinical and pathologic factors.
T Categories
| Stage | Description |
|---|---|
| T0 | No primary tumor identified after standard initial evaluation. This is the defining feature of CUP. No T stage classification applicable. |
N Categories
| Stage | Description |
|---|---|
| N/A | Lymph node involvement is a common clinical presentation, but no formal N staging for CUP. Clinical descriptions include cervical, supraclavicular, axillary, inguinal, mediastinal, and retroperitoneal nodal involvement. |
M Categories
| Stage | Description |
|---|---|
| M1 | Distant metastasis is always present by definition (occult primary with metastatic disease). No specific M substages are used. |
Stage Groupings
| Group | Criteria | Clinical Meaning | Five Yr Survival | Treatment Intent |
|---|---|---|---|---|
| Favorable prognosis | Includes patients with: single, small potentially resectable tumor; poorly differentiated carcinoma with midline nodal distribution; SCC involving cervical lymph nodes (2β5% of CUP); isolated inguinal adenopathy; poorly differentiated neuroendocrine carcinomas (PDNECs); women with papillary adenocarcinoma of peritoneal cavity; women with adenocarcinoma only in axillary nodes; men with blastic bone metastases and elevated PSA [2], [22], [26], [27]. Also patients with PS 0β1, low number of metastatic sites, low neutrophil-lymphocyte ratio [5]. | These patients have a longer median OS (12β36 months) and may benefit from site-specific therapy or locoregional approaches. | Not explicitly provided for favorable group; 3-year survival for SCC is 41.6% vs 3.5% for adenocarcinoma/undifferentiated tumors [2]. | Potentially curative or disease control with site-specific therapy (e.g., breast, germ cell, head/neck algorithms). |
| Unfavorable prognosis (80% of patients) | Includes: male gender assigned at birth; age β₯65 years; poor PS (ECOG β₯2); multiple comorbidities; multiple organ metastases (liver, lung, bone); nonpapillary malignant ascites; peritoneal metastases; multiple cerebral metastases; adenocarcinoma with multiple lung/pleural or bone lesions; high neutrophil-lymphocyte ratio [2], [5], [22], [24]. | Median OS 3β10 months; empiric chemotherapy offers limited benefit. Treatment is palliative with focus on symptom control. | 3-year survival for adenocarcinoma/undifferentiated: 3.5% [2]. | Palliative; symptom control, clinical trial preferred, systemic therapy on individual basis. |
| Favorable subsets with specific primary identified by IHC/molecular profiling | Patients in whom a putative primary is identified (e.g., breast, colon, lung, ovary, prostate, germ cell) and treated per disease-specific guidelines. | Outcomes align with the identified primary cancer; median OS may improve when site-specific therapy is used (e.g., 28.2 months vs 19 months in one RCT) [44]. | Varies by primary; not specified for CUP. | Site-specific therapy per NCCN disease-specific guidelines. |
Staging Pearls
- CUP is not staged with AJCC; instead, prognostic stratification is used based on clinical factors, histology, and newly validated nomograms [5].
- The Raghav nomogram (2021) incorporates gender, ECOG PS, histology, number of metastatic sites, and neutrophil-lymphocyte ratio to predict OS with concordance index of 0.71 [5].
- Favorable prognosis subsets include specific clinical-pathologic entities (e.g., women with axillary nodes, men with blastic bone metastases and elevated PSA) that should be identified and treated accordingly.
- Poor prognosis features (male, age β₯65, poor PS, multiple organ metastases, adenocarcinoma histology) define the majority of patients who are candidates for empiric chemotherapy or clinical trials.
- Primary site may emerge months to years later; 20β50% never identified even at autopsy [8], [15], [16].
- Detection of a primary site (via FDG-PET/CT or IHC) is associated with improved median OS (19.8 vs 8.5 months) in retrospective analysis [92].
Management PrinciplesClick to collapse
Occult primary (cancer of unknown primary, CUP) is a heterogeneous group of histologically confirmed metastatic malignancies for which the primary site cannot be identified during standard pretreatment evaluation. These tumors are characterized by early dissemination, aggressiveness, and unpredictable metastatic patterns. Median survival is 8 to 12 months, though select patients with favorable subsets (e.g., single small resectable lesion, midline nodal distribution of poorly differentiated carcinoma, squamous cell carcinoma [SCC] involving cervical lymph nodes, isolated inguinal adenopathy [SCC], poorly differentiated neuroendocrine carcinomas, women with papillary adenocarcinoma of the peritoneal cavity, women with adenocarcinoma involving only axillary lymph nodes, men with blastic bone metastases and elevated PSA) have median overall survival (OS) ranging from 12 to 36 months [2,4,5]. The treatment philosophy stresses palliation and symptom control in the majority; systemic therapy is palliative and does not significantly improve long-term survival for disseminated disease. However, tailored locoregional treatments or specific systemic regimens (e.g., fluorouracil-based for suspected colon primary, cisplatin-based for suspected germ cell tumor) may provide clinical benefit and prolong survival in favorable subsets. Multimodal approaches integrating surgery, radiation therapy (RT), and systemic therapy are individualized based on histology (adenocarcinoma/carcinoma not otherwise specified vs. SCC), clinical presentation, workup findings (including biomarker results), and performance status (PS). Enrollment in clinical trials is strongly encouraged.
Curative
Favorable prognostic subsets: single small potentially resectable tumor; poorly differentiated carcinoma with midline nodal distribution; SCC cervical lymph nodes (constituting 2%β5% of occult primary cancers); isolated inguinal adenopathy (SCC); women with papillary adenocarcinoma of peritoneal cavity; women with adenocarcinoma involving only axillary lymph nodes; men with blastic bone metastases and elevated PSA; poorly differentiated neuroendocrine carcinomas.
Tailored locoregional treatments (surgery, RT) and/or specific systemic therapy regimens (e.g., cisplatin-based for germ cell, fluorouracil-based for colorectal profile) may achieve prolonged survival. For isolated axillary adenocarcinoma, treat per NCCN Guidelines for Breast Cancer. For mediastinal adenocarcinoma in patients <40 years, treat as poor-risk germ cell tumor per NCCN Guidelines for Testicular Cancer or Ovarian Cancer.
Palliative
Disseminated metastases or unfavorable features (multiple organ involvement, poor PS, male gender at birth, age β₯65 years, multiple comorbidities, nonpapillary malignant ascites, peritoneal metastases, multiple cerebral metastases, adenocarcinoma with multiple lung/pleural or bone lesions).
Symptom control, clinical trial preferred, consideration of systemic therapy on an individual basis (symptomatic PS 1β2 or asymptomatic PS 0 with aggressive cancer). Specialized approaches (palliative thoracentesis/paracentesis, targeted therapies, novel RT). Psychosocial support and early end-of-life discussions.
Communication between clinician and pathologist is essential for workup to direct immunohistochemistry (IHC) staining pattern to the clinical differential diagnosis. Multidisciplinary team should include medical oncology, surgical oncology, radiation oncology, pathology, radiology, and supportive/palliative care services. For patients with peritoneal/ascites, consultation with surgical or gynecologic oncologist as appropriate. For inguinal nodes, gynecologic oncologist consult (in those with uterus and/or ovaries present). For retroperitoneal mass, consider gynecologic oncologist consult if CA-125 elevated. For head and neck presentations, treatment per NCCN Guidelines for Head and Neck Cancers.
Consider systemic therapy in symptomatic patients (PS 1β2) or asymptomatic patients (PS 0) with aggressive cancer. For patients with poor PS, prioritize symptom control, clinical trial, and supportive care. The use of intensive regimens like FOLFIRINOX, mFOLFIRINOX, or carboplatin/etoposide/paclitaxel is reserved for patients with PS ECOG 0β1 [34,36,37,33]. In patients with bone lesions and good PS, surgery for impending fracture and/or RT can be considered; for poor PS, RT alone is recommended.
Management PathwaysClick to collapse
Branching: Histology: adenocarcinoma or carcinoma not otherwise specified, Clinical presentation: isolated cervical nodes
Branching: Histology: adenocarcinoma, Clinical presentation: supraclavicular nodes
Branching: Histology: adenocarcinoma, Clinical presentation: axillary-limited
Branching: Histology: adenocarcinoma, Clinical presentation: mediastinum, Age stratification
Branching: Histology: adenocarcinoma, Clinical presentation: lung nodules (multiple) or pleural effusion
Branching: Histology: adenocarcinoma, Clinical presentation: peritoneal/ascites
Branching: Histology: adenocarcinoma, Clinical presentation: retroperitoneal mass, Histology consistent with germ cell tumor vs non-germ cell
Branching: Histology: adenocarcinoma, Clinical presentation: inguinal nodes, Unilateral vs bilateral
Branching: Histology: adenocarcinoma, Clinical presentation: liver, Resectable vs unresectable
Branching: Histology: adenocarcinoma, Clinical presentation: bone lesion, Isolated/painful/risk of fracture
Branching: Histology: adenocarcinoma, Clinical presentation: brain metastasis
Branching: Histology: adenocarcinoma, Clinical presentation: multiple sites
Branching: Histology: squamous cell carcinoma, Clinical presentation: head and neck nodes
Branching: Histology: squamous cell carcinoma, Clinical presentation: supraclavicular nodes
Branching: Histology: squamous cell carcinoma, Clinical presentation: axillary nodes
Branching: Histology: squamous cell carcinoma, Clinical presentation: mediastinum
Branching: Histology: squamous cell carcinoma, Clinical presentation: multiple lung nodules or pleural effusion
Branching: Histology: squamous cell carcinoma, Clinical presentation: inguinal nodes, Unilateral vs bilateral
Branching: Histology: squamous cell carcinoma, Clinical presentation: bone, Isolated/painful/risk of fracture vs multiple lesions
Branching: Histology: squamous cell carcinoma, Clinical presentation: brain metastasis
Branching: Histology: squamous cell carcinoma, Clinical presentation: disseminated metastases (multiple sites, bone multiple lesions, etc.)
Pretreatment EvaluationClick to collapse
Initial Evaluation
Workup (Biopsy and Pathology)
Additional Workup by Clinical Presentation β Adenocarcinoma
Additional Workup β Squamous Cell Carcinoma
SurgeryClick to collapse
Surgery plays a role in diagnosis (biopsy) and treatment of localized occult primary cancers, particularly for lymph node dissection in inguinal and axillary presentations, resection of isolated metastases (e.g., lung nodules, liver lesions), and palliative surgery for impending fracture in weight-bearing areas. Surgery is also considered for resectable retroperitoneal masses with non-germ cell histology. The primary goal is locoregional control in favorable subsets.
Core needle biopsy is preferred for initial diagnosis; FNA with cell block may be used if core needle biopsy is not feasible [OCC-1].
Surgical resection of isolated metastases (e.g., completely resectable lung nodules, liver lesions) can be considered when disease is limited and patient is medically fit.
Lymph node dissection (axillary, inguinal) is recommended for site-limited disease, especially for SCC; for bilateral inguinal involvement, bilateral dissection is recommended (RT alone is category 2B) [OCC-10, OCC-14].
For bone lesions with potential for fracture in weight-bearing areas, surgery for impending fracture is recommended in patients with good PS; otherwise RT alone is used [OCC-10, OCC-14].
If surgery is medically contraindicated for resectable liver lesions, treat as unresectable (disseminated metastases and/or locoregional therapy) [OCC-10].
Surgery may be considered for retroperitoneal mass with non-germ cell histology; RT can be used as alternative [OCC-9].
Procedures
Lymph node dissection (axillary)
Squamous cell carcinoma with axillary node involvement; adenocarcinoma with axillary-limited disease (but then treat per breast cancer guidelines).
Lymph node dissection (inguinal)
Squamous cell carcinoma or adenocarcinoma with inguinal node metastasis; for SCC, dissection is recommended; for adenocarcinoma, unilateral or bilateral dissection as clinically indicated.
Resection of lung nodules
Adenocarcinoma or SCC presenting with multiple lung nodules if completely resectable; may be considered for oligometastatic disease.
Liver resection
Adenocarcinoma with resectable liver lesion; if surgery is contraindicated, treat as unresectable.
Surgery for impending fracture
Adenocarcinoma or SCC with bone lesion(s) in weight-bearing area and good PS.
Radiation TherapyClick to collapse
Radiation therapy (RT) is used for definitive treatment of localized disease (especially for limited metastases), as adjuvant therapy after lymph node dissection, and for palliation of symptomatic lesions (pain, impending fracture, cord compression). Stereotactic body RT (SBRT)/stereotactic ablative radiotherapy (SABR) is recommended for oligometastatic disease (1β3 metastases) and pulmonary metastases [OCC-C].
Principles
- Definitive radiotherapy can be considered for patients with active disease localized to a single nodal site or isolated metastasis.
- Adjuvant RT after lymph node dissection is indicated if disease is limited to a single nodal site with extranodal extension or if there is inadequate nodal dissection with multiple positive nodes.
- Palliative hypofractionated RT is used for uncontrolled pain, impending pathologic fracture, or impending cord compression.
- Concurrent chemoradiation with capecitabine, fluorouracil, or cisplatin/fluorouracil can be given for selected presentations (e.g., presumed GI primary or SCC) [OCC-B 5,11].
- SBRT/SABR is particularly recommended for limited (1β3) metastases based on SABR-COMET trial [1] and for pulmonary metastases [2].
Dose Frameworks
| Name | Total Dose | Dose Per Fraction | Fractions | Schedule | Indication |
|---|---|---|---|---|---|
| SBRT/SABR | 48β60 Gy | 9.6β15 Gy (depending on fractionation) | 4β5 fractions | Typically over 1β2 weeks | Limited (1β3) metastases; pulmonary metastases [1,2]. |
| Adjuvant RT (after lymph node dissection) | 45 Gy with or without boost of 5β9 Gy | 1.8β2.0 Gy | 22β25 fractions for 45 Gy; plus boost fractions as needed | Conventional fractionation | Isolated supraclavicular, axillary, or inguinal nodal metastasis with extranodal extension or inadequate dissection with multiple positive nodes. |
| Palliative hypofractionated RT | 8 Gy (single fraction); 20 Gy (4β5 fractions); 30 Gy (10 fractions) | 8 Gy; 4β5 Gy; 3 Gy | 1; 4β5; 10 | Single day; 1β2 weeks; 2 weeks | Uncontrolled pain, impending pathologic fracture, impending cord compression. |
Approaches
| Name | Dose Fractionation | Concurrent Chemotherapy | Indication | Key Trial | Toxicities |
|---|---|---|---|---|---|
| Definitive RT (including SBRT/SABR) | 48β60 Gy in 4β5 fractions for oligometastases; other definitive regimens may be used for head and neck or mediastinal presentations per site-specific guidelines. | May be given with capecitabine (625β825 mg/m2 PO BID Days 1β5 weekly) or fluorouracil (200β250 mg/m2 CIV daily Days 1β5 weekly) for presumed GI primary; cisplatin/fluorouracil for SCC (cisplatin 75β100 mg/m2 Days 1 and 29 + fluorouracil 750β1000 mg/m2 CIV Days 1β4 and 29β32 with RT, or cisplatin 15 mg/m2 Days 1β5 + fluorouracil 800 mg/m2 CIV Days 1β5, 21-day cycle for 2 cycles with RT) [OCC-B 11]. | Limited nodal or extranodal disease, especially if unresectable or for organ preservation. | SABR-COMET [1], Gomez et al. [2] for oligometastatic NSCLC. | Fatigue, dermatitis, esophagitis, pneumonitis (depending on site). With concurrent chemotherapy, increased mucositis, hematologic toxicity. |
| Adjuvant RT | 45 Gy over 5 weeks to nodal basin Β± boost 5β9 Gy. | Not routinely used; adjuvant systemic therapy may be given sequentially. | After lymph node dissection for SCC or adenocarcinoma with extranodal extension or inadequate dissection. | Not specifically reported in CUP; extrapolated from head and neck and other guidelines. | Local skin reactions, fibrosis, lymphedema, xerostomia if head/neck region. |
| Palliative RT | 8 Gy/1, 20 Gy/4β5, 30 Gy/10 fractions. | Not typically used; systemic therapy may be given separately for symptom control. | Symptomatic bone metastases, impending fracture, cord compression. | Standard palliative regimens [OCC-C]. | Fatigue, local skin reaction, nausea (if large fields). |
Systemic TherapyClick to collapse
Systemic therapy is indicated for symptomatic patients with PS 1β2 or asymptomatic patients with PS 0 and aggressive cancer. The choice of regimen is based on histologic cancer type (adenocarcinoma vs. squamous cell carcinoma) and, if available, biomarker results (MSI/MMR, TMB, BRAF, NTRK, RET, HER2). For disseminated disease, treatment is palliative with limited efficacy; enrollment in clinical trials is strongly preferred. Regimens are listed in categories of preference (Preferred, Other Recommended, Useful in Certain Circumstances) as per NCCN. For adenocarcinoma, preferred options include carboplatin/paclitaxel [1,2] and cisplatin/gemcitabine [3]; for presumed GI primary, CAPEOX, FOLFIRI, mFOLFOX6 are preferred. For squamous cell carcinoma, preferred options include carboplatin/paclitaxel [1,2] and mFOLFOX6 [4,10]. Biomarker-driven therapies (e.g., dabrafenib/trametinib for BRAF V600E, pembrolizumab for dMMR/MSI-H or TMB-H, entrectinib/larotrectinib/repotrectinib for NTRK fusions, selpercatinib for RET fusions, fam-trastuzumab deruxtecan for HER2 IHC 3+) are recommended for selected patients meeting specific indications [OCC-B].
Key Regimens
Treatment Response AssessmentClick to collapse
Title
Follow-up and Response Assessment for All Occult Primaries
Timing
For patients with active disease or disease in remission, follow-up frequency should be determined by clinical need. For patients with no evidence of clinical disease, clinical follow-up with imaging every 6β12 months for up to 5 years is warranted [OCC-15].
Response Logic
-
Response assessment is driven by clinical evaluation (history, physical exam) and imaging (CT scans as clinically indicated). The guideline does not specify formal response criteria (e.g., RECIST) but standard oncologic response assessment should be used.
-
For patients with active and incurable disease, psychosocial support, symptom management, end-of-life discussions, palliative care interventions, and hospice care should be considered and utilized as appropriate [OCC-15].
Imaging Recommendations
-
Contrast-enhanced CT of chest/abdomen/pelvis is the primary imaging modality for follow-up. FDG-PET/CT may be used as alternative if contraindication to contrast or if needed for clarification [OCC-1A footnote d].
-
For patients with no evidence of clinical disease, imaging every 6β12 months for 5 years is recommended; after 5 years, imaging may be discontinued if no recurrence [OCC-15].
-
Diagnostic imaging studies for symptomatic lesions (e.g., bone scan for painful lesions, CT for suspected progression) should be performed as indicated.
Biopsy Or Salvage Logic
-
The guideline does not provide specific recommendations for re-biopsy at progression. However, biomarker testing (NGS, MSI/MMR, HER2 IHC) is recommended at initial diagnosis; repeat biopsy may be considered to identify new actionable alterations if clinical progression occurs and tissue availability permits.
-
If a primary site is subsequently identified during follow-up (e.g., through imaging or clinical changes), treatment should be redirected per the appropriate disease-specific NCCN Guidelines [OCC-7].